Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure  by Tsutamoto, Takayoshi et al.
Relation Between E~dothe 
Vascular Resistance in 
TAKAYOSHI TSUTAMOTO, MD, ATSUYUKI WADA, MD, YUKIHARU MAEDA, MD, 
TAKAKO ADACHI, MD, MASAHIKO KINOSHITA, MD 
otsu. hpan 
End&din-l is parr of a family of potent vasoconsrrictor 
peptides produced by the vascular endothelium (1). 
Endothelin-I was recently ideatild in human plasma by 
radiobnmunoasjay (2,3), and its level was found to be 
incrwed in patients with coagesGve heart failure compared 
with normal subjects (4,s). Moreover, numenus studies on 
the phanaaco!ogic effects of endothelin have led to the 
concept ihai it plays aa iaportaat pathophysiologic mk in 
systemic aad, in particular. pulmonary vasoconstliction 
6-15). Prev~cus udies have indlcatcd that many patients 
wit chroaic congsbtlva heart failure have increased pulmo- 
(J Aa Cdl C&Sot 1994$3:J42743) 
nary arty pressure aad resistance associated with an 
increase of vasoconstrictive nearohwnoral factors. 
More recently, ii was reputed that elevation of the 
arterial plasma endothelin4 level was correlated with the 
extent of pulmonary hypertension in patients with chronic 
cunges:ive heart ftilure, suggesting that endothe!in-I may 
act as a circula!iag hormone and may regalate pulmonary 
vascular resistance (16). lacreascd levels of varioar vase- 
constrictor neurohumolal factors, including eadatbelin-1, 
have been found in patients with congestive heart faiture, 
and these vasocoastrictors have some prognostic sipifi- 
caace (17-20). suggesting an important role for such fac- 
tors in the pathqhysiology of congestive heart failure. 
Endothelin-I is produced and secreted by the endotbelial 
cells of various organs and acts as both a circulating hor- 
mone and a local hamtone involved in the paracrine and 
autocrine systems. However. !he source of the increase of 
plasma endothelin-t in patients with congestive heart failure 
has not been clarified. Moreover, whether endothelin-I acts 
more as a ciflulating or a !ocal hormone has not been fully 
elucidated. Tbeiefo:e. the prevent study was perfomxd to 
determine the origin of plasma endothelin-t in patien’s with 
congestive heart failure and to investigate the local secretion 
of this hormone and its effect on the local vascular resis- 
tance. The findines of this studv reveal that eodotklin-l 
spillover is not found in the peripheral bat in the pulmonary 
sircolation, and only endothelin-I spillover in the lungs was 
foood to k an indqeadent and sigoiticaot predictor of 
increased polmonary vascular resistance among various 
vasoconstrictive oeorohomoral factors in patien:s with 
chronic congestive heiut failure. 
Patier&. We studied 62 patients with chronic coosestive 
heart failure who were witho+ renal failure and who under- 
went cardiac catheterization for clinical indications. In- 
formed consent was obttned from all patients kfore par- 
ticipation in the study, and the protocol was approved by tbc 
Human Investigatio& Comm&e of our institution. The 
sobiects -nere 32 men and 39 women 38 to 80 years old (meao 
a&58 years). Thirty-five patients had had a myocardi 
infarction 23 months kfore the study; II had dilated 
MdkXtIyOpathy: 9 had valvular heart disease: 4 had hyper- 
tensive heart disease; and 3 had hypertrophic cardiiyopa- 
thy. Tbiny-three patients were in New York Hew Ass& 
atioo functional class II: 17 were in class III: sod 12 were in 
class IV. Patients were assigned to two groopa according to 
their functional class: arooo I tfonctiooal class II. 33 oa- 
tient%J and gmup II (f&d& &ass 111 or IV, 29 p&e& 
Six patients in group II underwent repeat rigbl cardiac 
catheterization after >2 weeks and atkr the symptoms 
lessened. Forty patients were lreated witb diuretic drugs. 35 
with digitalis. aad 32 with vasodilators. All drags were 
discontinued a1 least 24 h before the study. 
Study protoeol. Seventy patients were given pnmcdii- 
lion (diazepam, 5 mg orally) and left to rest in kd in tk 
supine position for at least 20 min. Right-sided cardiac 
catheterization was oerformed usioa a 7F Swan-Ganz cath- 
eter, and a 7F pigtaiicatheter was u&d for Ien-sided cardiac 
catheterization. The heart rate was monitored by electrocar- 
diogram. Blood samples for measuring plasma endothelin-I 
were codected simultaneously from the right femoral artery 
and vein. Blood samples for measuring the plasma levels of 
norepinephrine, epinephrine. active renin concentration and 
angiotensin II were also drawn front the tight femoral vein. 
A Swan-Ganr catheter was inserted through the right fcmc- 
ml vein into the main pullpflnary artery. where the pressure 
was measured. The catheter was then inserted fanher into 
the pulmonary anery. and the pulmonary capillary wedge 
pressure was measured by inflating the balloon. Within 
2 min of this measurement, blood samples for the plasma 
endothelin-I assay were collected under fluomscopic gaid- 
ante from the main pulmonary artery and the site of palm@ 
nary capillary wedge pressure determination, as described 
previously (21). All blood sampling was done within 5 min 
before the adndnistratiau of contrast medium. Cardiac out- 
put was determined by the themmditution method immedi- 
ately after blood cottectian. Blood samples for the mcasore- 
ment of oxygen sahlrmion were also cc.uested from the 
femoral tiety and the site of polmomry &Uary wedge 
pressure measurement, and sight patients with an oxygen 
sataration <92% (below the normal raagc of arterial blood 
oxygea saturalion in oar Momtory) were excluded, as 
described prtviously (21). Therefore, 62 patients were ana- 
lyzed in the study. The oxygen saMat& of the blood oftbe 
polmooary capitky Matge region war slightly lower thao 
that of the feamlral artery (95.3 f 0.3 vs. %.2 * 0.2, p < 
0.09. 
-of- adaul&.lrlotber 
b factors. Blood for the measurement of 
p!aama eodotbelin-I levels was tmnaferred to a cbiued tak 
containing &yleaediamiaetetmacetic acid (EDTA) (I rag/ 
ml)aadapmtinbl(500kauikmiiinmivalorU/ml)aadthcn 
ccntrifaged at 3,OW q&S mbt at 4’c. Tlic piaama tbua 
obtaiaedwaaMorcdat-3OYootilitwasassaycd.Exbxc- 
tionofc&thelh+lwasperfomxdbyndxing2mlofpiasma 
with0.4mtof6o%mMhaoolcoo~0.25mJmtd 
F?epamtive Cl8 (Waters vy Division). The 
rezoveryratewascabxlatedtok72t3.99EC=5)by 
[‘Qtdothelia-lwithtltiamethcd.The~en&tbelitl-I 
kvels were dclcmtined by tuit@ an adii directai 
agidost syatbetii em&the&l (Per&s& MulmK&s) aild 
aa [‘2JI~i?dotklipl (Amuabam Japan). Tbk ardiiy 
abowed 100% cross-re&ivity slilh en&@&n-l, 7% with 
endothelin-2,7%witbeod&d&3aodI7%witbhwmnbig 
emdothelin-I. However, it did not QI*wLy( witbal@MeP 
sin I and II ,vuopcginmdbtmmt&alluwilu&pep 
tide.Tkminimald6tecUkkvelo(e&4bebh-lwasO.S 
p&be: tk iatenurry w&kieatofvariaGm vu 13%(0 = 
I0):andtbeitttraas¶aye~~ll%(rl=9). 
Thcmesa~endotbeli~lkvdwprI.J~O.2pJml~ 
2OagcmatcbulnomtalcontK4Mjecta. 
Bloodformeasurelnatoftbe~levelaof~ 
t&t II wu 1Asfemed to * chiikd tube catt+i+ ear.4 
(I mtdml), centrifogzd at 3,ooO rpo/U min at Cc, ti tk 
plmma thus obcaioed was rcacd at -3O’C until assay. 
plosmano&lepbrineamiepineF&iaecpnantrstioarwcrr 
measured by high perfonaancc liquid cbmmat~~:,rapby. 
plasma active nnin concentration vu meaaumd with a 
commercial renin immurm&otncttic rosy kit @inab&. 
Plasma angiotensia II kvelr we= meas& by a radii 
hnmoaoaaaay using specitic antibody diited a&tat ay* 
thetic aosiotenrin II by tk Special Research L&nato~ in 
Tokyo. This antibody had I& cross-~tivity witb aogic- 
tensin II. 0.3% crosxeactivit~ with mxiotensin I and no 
cross-reactivity witb endothelin-I, “as&r&i and atrial 
aatriuretic peptide. 
ctkahtba. Tkmeanbloodprersare,pulmoaaryvaa- 
c&r resistance and systemic vascular resistance were Cal- 
cula~edfmmthcslandardfamuhs.ThcioderoftbePmoum 
of cndothelin-I spillover in the lungs was detemdocd 
with the following fomrttla: (Endathetin.1 level at the site 
of pulmonary capillary wedge pressure determination - 
Endothclin-I level in the main pulmonary artery) x Cardiac 
output X (I - HematwritilMt) (ng/min). 
SW&at r&sls. All results were expressed as mean 
values 5 SEM. Comparison of the plasma endathelin-I 
levels at the various sites of blood sampling and the plasma 
endothelin-I levels of age-matched normal subjects. group I 
(mild ie811 failure) and group II (severe heart Like) was 
prfotmtd by one-way analysis of variance (ANOVA) with 
Schetf=Z test. Comparison of hcmodynamic variables aod 
WOCOtWiCtO~ faCtMs bctWW! gr0”Qs I and !I was QW 
formed by the unpnired I test. Stepwise multivariate regres- 
siott analysis was used IO detect independent predictors of 
pt&tonq vascular resistance among the following vaso- 
constrictor factors: plasma active rain concentration. 
plrwru angiotensin II. plasma norcpinepbrim. femoral ve- 
ttws plasma endothelin-I level and pulmonary endothelin-I 
spillover. Linear rqressiott analysis was used to determine 
the som*tions helwcen endothclitt-l spillover in the lungs 
awl polmcaary vascttlar resistance between the femoral 
versxts endo(helirrl kvcl and pulmonary vascular resistance 
and bchveca the plasma norepirqihrine level and pulmonary 
vufular r&s’W~~c. A p value < 0.05 was considered 
statistically sitpdficaot. 
ReSUlIS 
Ikm+%~& dab. Cardiac index and left ventricttlat 
eMiott fraction were sktdficantly lower in group II (fuw 
t&al clau III or IV) tlian in g&p I (futtc~ottal class II) 
flatde 1). In contrast, pulmonary capillary wedge pressure 
wa.9 sign&candy bigher in gmop II than in group I (20.3 r 
1.2 vs. 8.4 k 0.8 mm Hg. P < 0.001). Both pulmonary and 
systemic vascular resistance were significantly higher in 
mp II lhatt in grasp I @ulmotwy vascular resistance 
228 + 18 vs. II6 f 6.1 dynes*rxm-s. p < 0.001: systemic 
vasctdar esistaxe 1982 * $3 vs. I.597 % 48 dyoesscrKs, 
p > 0.01). 
Pkm9 mdatkdkl cwxntratkw. The femoral venous 
pkma endothelio-I concentration in the 62 patients with 
mn8estivc heart failure was significantly higher than that in 
theage-matched control subjects, and it increased in relation 
to the severity of congestive heart f&are (Fig. 1). Plasma 
mdothelin-I levels at the various sites of blood samplings 
wre determined ia the 62 patients with chronic congestive 
heart failure. The plasma endo!helin-I kvnl in ths main 
pulmonary artery was 3.1 + 0.23 pglml; the level at the 
pulmonary capillary wedge region was 4.6 2 0.36 pg/ml; the 
femoral artery level was 3.2 t 0.28 pglmi: and the femonl 
venous endothelin-l level was 3.5 2 0.2s pgiml (Fig. 21. 
The plasma endothelin-I concentration increased signiii- 
cantly from the main pulmonary artery to the pulmonary 
capillary wedge region ip < 0.01. ANOVA with Sahel 
test). Them was no significant dienence between the plasma 
endothelin-l level in the femoral artery and femoral vein 
(Fig. 2). 
Comparison op vitas I¶&? between groups 1 
(miht heart faihwe) n (sevem failwe). The plasma 
active win concentration and the angiotensin II and nor- 
epinephrine levels were signikcant:y higher in group II than 
in group I (Table 2). At all sites of blood samplings. the 
plasma endothelin.1 concentration was also signiticantly 
higher in group II than in group i (Fig. 3). Moreover. 
endothelin-I spillover in the Ittogs was significantly gre;\ter in 
group 11 than in group I(5.4 ? 0.52 vs. I.1 ? 0.22 ngJml, 
p < 0.001) (Table 2). 
Figs 1. Plasma concentration of endothelin-I in 20 age-matched 
normal subjects (contml) and in 33 patients with mild (group I. 
functional class II) and 19 patients with severe &mup II. functional 
class It, or IV) heart failure. Data are meai? value f; SEM. “p < 
0.01. analysis of variance with Schel test. 
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Figw 2. Plasma andothelin (ET).1 levels at various shcs of blood 
coUe&n in 62 patients with chxmie heart failure. tp < 0.01. 
analysis of variance wilh Sahel test. FA = righl femoral anay. 
FV - right femoral win; PA = main pulmonary artery; PC = 
pulmonary capillary wedge repicn. Data are mean value 5 SEM. 
vasueoastrlctor fartori. The timoral venous plasma 
endothelin-I concentmtion siaailicantlv correlated with oul- 
munary vascular resistance (r-= 0.44,; 4 0.01) (Fig. 4). ‘he 
plasma norepinephrine concentration was also correlated 
with oulmonarv vascular resistance (r = 0.30. D < 0.05). 
Among the various vasoconstrictor factors studi& (plasma 
active renin concentmtion, angiotensin II, norepioephtine. 
femoral venous eodothelin-I. pulmonary endothelin-I spiN- 
over), only pulmonary endothelin-I spillover was found to 
be au independent and significant prediclor of pulmonary 
vascular resistance in patients with chronic congestive heart 
failure (r = 0.82, p < O.OOI) (Fig. 5). In six patients in group 
II who underwent repeat cardiac catheterization before and 
after symptoms of congestive heart failure lessened, pmdw 
tion of endothelin-l in the lunas decreased in association 
with the decrease of pulmon&vascular resistance and the 
lessening of symptoms (Fig. 6). 
Discussion 
Maln sourn of @asma endothelin-1 Itv.’ ltt patients with 
ecqestlve heart failure. We demonstrated that endothelin-I 
spillover is predominant in the pulmonary vascular beds but 
not in Ihe peripheral circulation of patients with chronic 
congestive heart failure. Moreover. the spillover of 
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Figure 3. Compariwn of plasma endothelin (ETI-I levels al various 
sites 01 blood colkction bewccn patients with mild lgroup 1. @ten 
drrlal and severe Qroup II. seltd drctes) heart failure. Data we 
mean value t SEM. tp < 0.01 versus group I. 
endothelinl in the lungs was significantly higher in patients 
with severe than in those with mild congestive hean bsre. 
F’revious repotis (4.5) have shown that plasma endothelin-l 
levels increased in relation to the severity of congestive 
heart failure. but the oriain of the increased endothelin-t 
level has remained unclear. Yoshibayashi et al. (22) demon- 
strated that plasma etxlothelin-I levels were elevated in 
patients withcongenital heart defects with pulmonary hyper- 
tension, and this was due to the iucreawd production of 
endothelin-I in the pulmoaary circulation. as demonstrated 
by blood sampling from the pulmonary artery and the 
pulmonary vein or the pulmonary capillary wedge region. 
However, they could noI rule out the possibility of pmduc- 
tion in the peripheral circuMoa in these patients. Because 
the plasma endothelin-I level was increased in patients with 
systemic hypertension (23.24) and cardiogenic shock (251. 
we hypothesized that endothelin-I is produced sot only 
in the pulmonary circulalion but also in the peripheral 
circulation in patients with chronic congestive heart failure. 
However, there was no significant diflerence in plasma 
endothelin-I levels between the femoml anery and vein 
in the present study, suggesting that the increase in 
endothelin-I is mainly contributed to by spillover in the 
lungs. Moreover. the plasmaendolhelin-I level was higher at 
all sites of blood sampling in the patients with severe 
compured with those with mild congestive heart failure. In 
addition to the significantly higher spillover of endothelin-I 
in the lungs of patients with severe congestive heart failure. 
these findings suggest that the main source of circulatmg 
ettduthelin-I is the pulmonary vascular eodotheliel cells. 
In the present study. plasma endotheliu-I levels increase 
in relation to the severity of congestive heart failure. as 
previously reported (4). However. the functional role of 
circulating ettdothelin-I remains uncertain. The plasma con- 
centration detected in patients with severe con&stive heart 
failure in the mxnt study was still below the threshold for 
inducing a &actile &ponse in vitro or in viva (1.9). 
However, an animal study has shown that infusion of 
endathelin-I. with elevation of the olasme level to twice the 
control level (similar to the levels found in the present 
study), produced significant hemodynamic effects (26-28). 
Further studies on the role of endothelin-I in congestive 
heart failure could utilize antibodies against the endothelin-I 
receptor. but such studies are diicult to perform in patients 
with congestive heart failure. As Vane et al. (29) have 
suggested, the circulating level of endothelin-I may only 
indiiclly reflec: local vesadu production, and concentra- 
tions in the vascular wall may be several orders of magnitude 
greater than those measured in the plasma. 
Possible mechanisms causing an increase of endothelin-I 
in congestive heart failure include increased production 
stimulated by either hemodynamic or neurohumoral factors 
or decreased clearance or metabolism of the peptide. The 
FiRwe 5. Corrrlation betwen endothelin tET)-I spillover in the 
lungs rmd pulmonary vascotar resistance in paiieets with chronic 
hcnr! fviturc. Endothelin-I spiltover in tk lucg = (Endottelin-I 
level in puhnunary capillary wedge region - Endotheliwl level in 
man pulmonary artery) x Cardiac output X tt - HeaatocritllW) 
tnimml. 
possibility that the metabolism of endothelin-I is decreased 
cannot be neglected in patients with congestive heart failure. 
Plasma endothelin-I levels are also increased in patients with 
renal failure (30). The present study excluded patients with 
renal dysfunction, but decreased metabolism of endothelin-1 
in the kidney could still have contributed to the high plasma 
level of this peptide in our patients with congestive heart 
failure. previous studies have demonstrated that messenger 
RNA and the receptorof endothelin are present in the lungs, 
and that the endothelin is produced and cleared in ihe 
oulmonarv circulation in animal exwiments (31-34). In the 
bresent study. our calculated v&s for endothelin-I spill- 
over may have underestimated the true production due to 
the neglect of clearance by the pulmonary circulation. How- 
ever. even taking into account the possible effect of 
clearance. the lung still appears to be the main source and 
target organ of endothelin-I in patients with congestive 
heart fdlurc. Moreover. a significant decrease in plasma 
endothelitt-I from the pulmonary capillary wedge region to 
the femoral artery indicates the quick clearance or metabo- 
lism of this peptide through the circulation. 
flelation between endothelimt spillover in the lungs and 
pulmonary vawUar resistance, We also demonstrated a 
close correlation between endothelin-I spillover in the pul- 
monary circulation and pulmonary vascular resistance. 
Among the various vasoconstrictor factors investigated, 
only endothelin-I spillover in the lungs was independently 
and significantly correlated with pulmonary vascular resis- 
lance. This finding may support the idea that codothetin-I 
is a local hormone (35). that is, that it acts mainly in e 
parecrine maoner on the pulmonary vaw~lwbeds in petieota 
with chronic conaestive heart failure. Endothelio-I ha 
a duel action be&se it is a potent vasomnshictor. sod it 
also cmtses vasodiktion mediated by the production of 
endothelium&rived reltina factor or orostacvclin (33). 
The physiologic e5ect of ck&d cndoth;lin-l kick is‘sill 
controversial. Although endothclin.1 acts as both a vasocw- 
strictor and a vasodiktor in the peripheral circulation (36), 
this peptide acts mainly es P vasoconstrictor in the pulmo- 
nary circulation in animal experiments. Administration of 
endothelin-1 results in an increase in pubnooery artery 
pressure in experimental models (10-14). Furthermore. sim- 
ilar observations have also been made with human pttbnb 
nary arteries studied in vitro. Thus. endothelin-I produced in 
the lungs, es observed in the present study, may act as a 
vamconstrictor in the regulation of pulmonary vescular 
resistance. We were able to study six patients with severe 
congestive heart failure both before end eller treatment. In 
these patients, plasma codothelin-l levels decreased as their 
symptoms lessened. We also found ihat a decrease in 
pulmonary vascular resistance accompanied the decrease in 
endothelin-1 spillover in the lungs of !hese patients. These 
results indicate a strong relation between endothelin-I spill- 
over io the lungs and pulmonary vascular resistance end 
suggest that endothelin-I production in the longs may rego- 
late pulmonary vasatlar resistance in patients with conges- 
tive heart failure. In a rat model with monocmtaline-induced 
polmottay hypertension, Miyaochi et al. (37) recently re- 
ported that the progression of pulmonary hypertension was 
attenuated bv the edmb&ration of a selective endothelin 
type A reciptor antagonist (BQ-123). and this finding 
stroogly supports oar hypothesis. In addition, endothdin-I 
regulates not only vaeutkr tone but also proliferation of 
vasctdar smooth mosck cells (381, end therefore sustained 
high levels of this peptide may have an adverse pathophys- 
iologic elTect in congestive heart failure. Our prelimiwy 
finding (4) that high kvels of endothelin-1 provid-z important 
pmgoostic ioformatkn in caogestive heart feihre also sop 
ports this hypothesis. 
&dy llmlwkn. In the present study, blood samples 
were colkcted from the pokwnwy capilkry wedge region to 
co&m the prwlwtioo of endothelinl in the p~&onary 
circoktkn. Blood samples were obtahied in this way be- 
awe it is not ethkal to ptfomt ttaosscpml catheteMition 
through (he fosse ovalis to obtain blood from the pohnowy 
vein. Otu preliminary data showed oo apparent d&ace in 
plasma eo&Min-I kvels io the pulmooary vein nod pal- 
with a&l d&t b in p&cats with mikal valvokr 
stenosis who had o&qone ptwtaoeow tranwenoos mi- 
wal comtissomtomy. we previously used the seme mah- 
odstoevaluptetheutmctiondatrkltwhtretkpepcide 
attdthcpmhctioudcyclic~mowpbosdbslek 
the mdmonarv cinulation i?l!. Yoshiivbshi et al. 0.2) also 
ud~summethodrru;hdse~inibsprcxnt;t;dyto 
evaluate the pmdumi~~ d ertdothclbt-I bt the lung. How- 
ever. blood sempliog from the polmmwy wpilkry wedge 
positknmeyrhkverlimiuds@ingwiodowdthe 
pokwnaryvascutbedcompwedwitbthatdpohncay 
vemusbIocd.Indecrl,mncdtkblwdinthepllmowy 
capihy wedge position may have been exposed for * 
secoadthnctolhccqilkry&eokrmembmoe,botthiris 
probably onlikely in the present stody because oxygen 
satoratknoflhebkcdiothe@nonmycdpilkryw~ 
wion was slightly lower tbao that in tlw femoral artery 
(9i.3 + 0.3 vs. %.2 * 0.2. p c 0.05). 
In addition. local endothelkl iniorv doe to balloon iofla- 
lion may i&ence endotbelin-I &Is in the pohnowy 
apilkry w&e region. However, we bclkve that the in- 
crease in endotlxlin~l detected in plume from this regko is 
oat simply due to balkca injury because cndoth+lin~l spill- 
over was correlated with the we&y of heart falhue and the 
level of pulmonary vascular nristaocc. lodeed. Alfred et al. 
(39) have rqnwted that local and systemic exlothelin kvels 
did not iocrcase after balloon iqjwy by prcuteneous ttaw 
kmkal Eomnmy angioplasty. 
Cwd&m~. Plasma endothelin-I kvelo are elevated in 
patients with chronic congestive heart fpilurr, and the main 
origin of this peptide is not the peripheral but the pulmonary 
vascular bed. The close correlation between endotltelir-I 
spillover in the lungs and ptdmonery vascular resistance 
suggests that this peptide acts mainly as a laal factor rather 
than as a circulating hormone. These results indicate a 
possible impOrtant role of endothelin- I in the palhogenesis of 
congestive hean failure. especially in the pulmonary circu- 
lation. 
